Utilization of small-molecules to target CA IX for delivery of anti-cancer therapeutics has advantages over using antibodies, as they exhibit deeper tissue penetration, faster pharmacokinetics, lower immunogenicity, and they are able to be produced by total organic synthesis expediting their production [93]. Here, CA9 is linked to cancer.